Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report.

Roje Bedeković M, Ivona J, Bosnar Puretić M

Journal of medicine and life1 Jun 2026

PMID42602665 (opens in a new tab)PMCIDPMC13474398 (opens in a new tab)DOI10.25122/jml-2026-0081 (opens in a new tab)PepBankPUB-42602665
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Basilar artery occlusion (BAO) is an uncommon yet devastating cause of posterior circulation stroke, frequently resulting in severe disability or death despite successful reperfusion. We describe a 67-year-old woman with multiple vascular risk factors who presented with acute BAO and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction [TICI] grade 3), with adjunctive Cerebrolysin therapy administered subsequently. Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale (NIHSS) score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) by day 3. Clinical recovery was sustained throughout the 12-month follow-up period, with only mild residual gait disturbance noted at discharge. No adverse events attributable to Cerebrolysin were observed. Successful reperfusion remains the key determinant of outcome in BAO, and no causal inference can be made regarding Cerebrolysin. This case adds to the limited evidence on the use of Cerebrolysin as an adjunct to reperfusion therapy and supports further investigation in controlled studies of posterior circulation stroke.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a woman with basilar artery occlusion, reperfusion followed by adjunctive Cerebrolysin was associated with NIHSS improvement and complete neurological recovery.

    In plain wordsIn a woman with basilar artery occlusion, reperfusion followed by adjunctive Cerebrolysin was linked to NIHSS improvement and complete neurological recovery.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS improvement
    Study

    n = 1

    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    NIHSS score
    7
    before the reported decrease to 2
    NIHSS score
    2
    within 24 hours
    NIHSS score
    0
    complete neurological recovery by day 3

    Source sentences

    Summary
    Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale (NIHSS) score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) by day 3.
    1 context sentence
    Summary · context
    We describe a 67-year-old woman with multiple vascular risk factors who presented with acute BAO and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction [TICI] grade 3), with adjunctive Cerebrolysin therapy administered subsequently.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a woman with basilar artery occlusion, recovery after reperfusion and adjunctive Cerebrolysin persisted throughout follow-up.

    In plain wordsIn a woman with basilar artery occlusion, recovery after reperfusion and adjunctive Cerebrolysin persisted throughout follow-up.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSustained clinical recovery
    Study

    n = 1

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Clinical recovery was sustained throughout the 12-month follow-up period, with only mild residual gait disturbance noted at discharge.
    1 context sentence
    Summary · context
    We describe a 67-year-old woman with multiple vascular risk factors who presented with acute BAO and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction [TICI] grade 3), with adjunctive Cerebrolysin therapy administered subsequently.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 03HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a woman with basilar artery occlusion, mild gait disturbance remained at discharge after reperfusion and adjunctive Cerebrolysin.

    In plain wordsIn a woman with basilar artery occlusion, mild gait disturbance remained at discharge after reperfusion and adjunctive Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableResidual gait disturbance
    Study

    n = 1

    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    Clinical recovery was sustained throughout the 12-month follow-up period, with only mild residual gait disturbance noted at discharge.
    1 context sentence
    Summary · context
    We describe a 67-year-old woman with multiple vascular risk factors who presented with acute BAO and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction [TICI] grade 3), with adjunctive Cerebrolysin therapy administered subsequently.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  4. 04HumanNot a test of Cerebrolysin aloneCase report or seriesSafety outcome

    In a woman with basilar artery occlusion, no adverse events attributable to adjunctive Cerebrolysin were observed.

    In plain wordsIn a woman with basilar artery occlusion, no adverse events attributable to adjunctive Cerebrolysin were observed.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableAttributed adverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No adverse events attributable to Cerebrolysin were observed.
    1 context sentence
    Summary · context
    We describe a 67-year-old woman with multiple vascular risk factors who presented with acute BAO and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction [TICI] grade 3), with adjunctive Cerebrolysin therapy administered subsequently.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.